About Us

Quotient Bioresearch – Answers Through Innovation

Quotient Bioresearch is a leading provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide.

Driven by our passion for scientific excellence, our vision is to be recognised as the premier global provider.

Our early stage and specialist drug development services are underpinned by a unique combination of medical, chemical and biological expertise. We continually strive to deliver the highest quality service to support our clients’ endeavours in their development of new and pioneering medicines and products.

Our innovative range of capabilities span:

Radiochemistry
Drug Discovery and Metabolism
Agrochemical and Chemical Development

Phase l/lla development
Drug Product Optimisation
14C Enabled Drug Development

Biomarkers
Bioanalysis
Microbiology

These can be provided independently or integrated into tailored work programmes, including:

¹⁴C enabled Drug Development – delivered using our unique Synthesis-to-Clinic^TM service
Translational Pharmaceutics - enhances the speed, success and value from your pivotal phase I clinical studies.

Founded in 2007, Quotient Bioresearch is part of the Quotient Group, incorporating HFL Sport Science, established and grown through a combination of acquisition and organic growth.

We believe people, not technology, can aspire to excellence. Having great people is how we deliver a great service and why the Quotient experience is so different.